ClinicalTrials.gg
RecruitingNCT07483723PROGLYSOPKUpdated Mar 19, 2026

Glucose Profiles in Women With Polycystic Ovary Syndrome

An interventional study of sensor and Age reader in Polycystic Ovary Syndrome, Glucose Profile and Insulin Resistance, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Polycystic Ovary Syndrome with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Polycystic Ovary Syndrome · France.

Planned enrollment
6th of 13
80 · median 52
Started
2026
with 4 others
No phase
8 of 21
5 open now
Registered
18th of 21
by date
Lead sponsor
1 of 21
Centre Hospitalier Universitaire, Amiens

Among the 21 studies in Polycystic Ovary Syndrome with a site in France, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 with no phase, and was the 18th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

9 of the 21 studies in Polycystic Ovary Syndrome with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Polycystic Ovary Syndrome with a site in France, or all of them as a file.
02

Study summary

Polycystic ovary syndrome is a very common condition that is associated with metabolic complications. Patients with polycystic ovary syndrome exhibit insulin resistance and are at greater risk to develop type 2 diabetes. This syndrome is heterogeneous, classified according to 4 phenotypes (A-D). It seems that certain phenotypes are less exposed to insulin resistance and metabolic complications. However, only a few studies have evaluated the glucose profile according to phenotype. New technologies now make it possible to monitor glucose levels continuously. The aim of this project is to evaluate glucose profile parameters using continuous glucose monitoring, and to compare these profiles according to different PCOS phenotypes.

03

Conditions studied

  • Polycystic Ovary Syndrome
  • Glucose Profile
  • Insulin Resistance
  • Continuous Glucose Monitoring

Keywords

  • polycystic ovary syndrome
  • phenotype
  • glucose profile
  • insulin resistance
  • continuous glucose monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years at inclusion criteria
  • Patient with polycystic ovary syndrome, defined by the presence of at least 2/3 irregular menstrual cycles, clinical or biological hyperandrogenism, polycystic ovary morphology (pelvic ultrasound) or elevated AMH levels, after the exclusion of other disorders.
  • Agreed to carry the FSL pro
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breast-feeding
  • Differential diagnoses: hyperprolactinemia, dysthyroidism, Cushing's syndrome, congenital adrenal hyperplasia, virilizing tumor (ovarian or adrenal), intake of exogenous androgens
  • Pre-existing diabetes
  • Patient treated within 3 months prior to inclusion/data collection with estrogen-progestin , progestin contraception, antidiabetic drugs, inositol, antiandrogen
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Phenotype A

    oligomenorrhoea or amenorrhoea + hyperandrogenism + polycystic ovary morphology or elevated AMH levels

    Device: sensor · Device: Age reader

  • Experimental
    Phenotype B

    hyperandrogenism + oligomenorrhoea or amenorrhoea

    Device: sensor · Device: Age reader

  • Experimental
    Phenotype C

    hyperandrogenism + polycystic ovary morphology or elevated AMH levels

    Device: sensor · Device: Age reader

  • Experimental
    Phenotype D

    oligomenorrhoea or amenorrhoea + polycystic ovary morphology or elevated AMH levels

    Device: sensor · Device: Age reader

Interventions

  • Devicesensor

    Free-style-libre pro sensor application for 14 days

  • DeviceAge reader

    Analysis of glycation end products by AGE reader

06

What researchers measure

Primary outcomes

  1. Time in range (TIR)

    Time in range (TIR) variation between 4 groups

    Time frame: 14 days

Secondary outcomes

  1. Time in tight range

    Time in tight range (70-140 mg/dl) variation between 4 groups

    Time frame: 14 days

  2. Time above the range

    Time above the range variation in 4 groups

    Time frame: 14 days

  3. Average glycaemia

    Time frame: 14 days

  4. Glycemic variability

    Time frame: 14 days

  5. Presence of hypoglycaemia

    Presence of hypoglycaemia

    Time frame: 14 days

  6. HbA1C

    Time frame: 14 days

  7. Oral glucose tolerance test data

    Time frame: 14 days

  8. Evaluation of glycation end products by AGE reader

    Time frame: 14 days

  9. Assessment of insulin resistance

    Time frame: 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 18 months is close to that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 19, 2026
StartActual
Jan 6, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483723
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Jan 6, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Abdallah Al-Salameh, Pr
Contact
Al-Salameh.Abdallah@chu-amiens.fr
33+3.22.08.83.71

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion